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Summary
Background—von Willebrand factor (VWF) variant c.2771G>A; p.R924Q has been described
as a benign polymorphism or a possible marker for a null allele and been associated with mild
bleeding phenotypes. It was identified in several patients in recent type 1 von Willebrand disease
(VWD) studies.
Objectives—To determine whether the p.R924Q allele contributes to reduced VWF levels and
type 1 VWD.
Methods—1115 healthy controls and 148 index cases from the MCMDM-1VWD study were
genotyped for c.2771G>A; VWF and FVIII levels were analysed in ABO blood group stratified
individuals and the p.R924Q variant was expressed in 293 EBNA cells.
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Results—c.2771G>A was present in six index cases, five of whom had a second VWF variant
which likely contributed to phenotype. A common core haplotype identified in families, which
included the rare G allele of c.5843-8C>G was present in the majority of 35 c.2771G>A
heterozygous controls. c.2771G>A contributed about 10% variance in VWF and FVIII levels in
controls and 35% variance when co-inherited with blood group O. Recombinant p.R924Q VWF
had no effect on in vitro expression and heterozygous family members had normal VWFFVIII
binding and normal clearance of VWF and FVIII.
Conclusions—The allele bearing c.2771A leads to reductions in VWF and FVIII levels
particularly in combination with blood group O. Its inheritance alone may be insufficient for
VWD diagnosis, but it appears to be associated with further VWF level reduction in individuals
with a second VWF mutation and it contributes to population variance in VWF and FVIII levels.
Keywords
ABO blood group; founder effect; factor VIII; R924Q; type 1 von Willebrand disease; von
Willebrand factor
Introduction
Three multicentre studies in the European Union (EU), Canada and the United Kingdom
(UK) [1-3] have led to increased understanding of the molecular basis of type 1 von
Willebrand disease (VWD), a partial quantitative deficiency of plasma von Willebrand
factor (VWF). Candidate VWF mutations were identified in approximately 65% of type 1
VWD index cases (IC) and included many different mutations throughout the VWF gene
(VWF), mostly missense alterations (80%). A small proportion of sequence variants were
seen consistently in all three studies and included c.2771G>A in exon 21, predicted to result
in p.Arg924Gln (p.R924Q).
c.2771G>A was first reported in a patient with type 2N VWD, but was thought to be a
benign polymorphism as recombinant VWF carrying the p.R924Q change bound normally
to FVIII (VWF:FVIIIB) and the patient had a further novel 2N change, p.C1060R which
could explain the phenotype [4]. The EU and Canadian studies each reported c.2771G>A as
a candidate mutation [1,2], whereas the UK study considered it likely to be a silent variation
[3,5]. It results in substitution of a basic by an uncharged amino acid in a highly conserved
region of VWF. Analysis of patient mRNA has recently identified a novel truncated
transcript resulting from activation of a cryptic splice site in exon 28 in an individual
compound heterozygous for the variant (p.[R816W]+[R924Q]) [6].
In this study, the p.R924Q allele appeared to contribute to phenotype in IC with type 1
VWD and to reductions in both VWF and FVIII in heterozygous healthy controls (HC). The
majority of heterozygous individuals share a common founder haplotype that likely
originated in Eastern Europe. Recurrence of p.R924Q on different haplotypes along with
acquisition of further sequence variants on ancestral p.R924Q alleles may contribute to the
variable behaviour observed.
Patients and Methods
Study population
Genomic DNA was available from the MCMDM-1VWD study [1] for IC (n=148)
historically diagnosed with type 1 VWD, their affected and unaffected family members
(AFM; n=278, UFM; n=311) and healthy controls (HC; n=1115). Participants were
predominantly Caucasian and were recruited by partners P1-P12, located in nine European
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countries [1]. FVIII coagulant activity (FVIII:C), VWF antigen (VWF:Ag), ristocetin
cofactor activity (VWF:RCo), bleeding score (BS), multimer classification and ABO blood
group were determined previously [7-9].
Ability of VWF to bind recombinant FVIII was determined in IC and AFM as described
[10]. Results are expressed as the ratio of the slope of test plasma to that of a HC. Normal
range (NR; mean ±2SD) was calculated from slope ratios in 63 UFM with no VWF mutation
identified.
Genotyping
The c.2771G>A variant (rs33978901) was genotyped using matrix-assisted laser desorption/
ionization time-of-flight mass spectrometry (MALDI-TOF MS) using a Sequenom
MassARRAY system and iPLEX technology (San Diego, CA, USA). Amplification and
primer extension were undertaken according to manufacturer’s instructions and primers
listed in supplementary Table 1. Genotype in selected individuals was confirmed by DNA
sequencing exon 21 using primers in supplementary Table 1, or by comparison with
previous conformation sensitive gel electrophoresis data [1].
Haplotype analysis
Determination of haplotype associated with c.2771G>A was achieved by genotyping eight
VWF single nucleotide polymorphisms (SNP) with known population frequencies;
c.-2527A>G (promoter, rs7965413), c.1411G>A (exon 12, rs1800377), c.2365A>G (exon
18, rs1063856), c.4141G>A (exon 28, rs216311), c.5843-8C>G (intron 34, rs34444862), c.
5844C>T (exon 35, rs216902), c.8116-20A>C (intron 49, rs2270152), c.8155+50C>T
(intron 50, rs2270151). Genotyping was performed by allelic discrimination using the 5′
nuclease TaqMan assay (ABI 7900; Applied Biosystems, Warrington, UK) as described [1]
or direct DNA sequencing. Primers are listed in supplementary Tables 2 and 3.
Expression of recombinant VWF containing p.R924Q
Site directed mutagenesis of full length VWF cDNA was carried out using the Quick Change
kit (Stratagene, Kassel, Germany). Mutagenic primers carrying the required base-exchange
at a central position were 40bp long. The expression vector VWF-pcDNA3.1 containing
mutant and wild-type (wt) VWF cDNA, was used to transform Top10 supercompetent E coli
(Invitrogen, Karlsruhe, Germany). Plasmids were purified by the Endofree Plasmid Maxi
Kit (Qiagen, Hilden, Germany). 2×106 293 EBNA cells (Invitrogen, Karlsruhe, Germany)
were transiently transfected with 4 μg mutant or wt full length VWF cDNA by liposomal
transfer (Lipofectamine 2000, Invitrogen). Cells were grown for 72h (24h in DMEM
(Invitrogen) with 10% (v/v) FBS and 48h in serum free IMDM (Sigma) with 2% (v/v)
Ultroser G (Invitrogen)). VWF secreted into the medium was concentrated in Centricon
tubes to 1/10 of the original volume prior to analysis. To analyze intracellular VWF,
transfected cells were lysed by three rounds of freezing (−80°C) and thawing in lysis buffer
(0.1 M Tris-HCl pH 8.0; 0.6% (v/v) Triton X-100). Recombinant VWF (rVWF) was
analysed as described [11].
Statistical analysis
All internet-based statistical and sequence analysis tools were accessed April 2009. Hardy-
Weinberg equilibrium, haplotype prediction and calculation of linkage disequilibrium were
assessed using SNPStats (http://bioinfo.iconcologia.net/index.php?module=Snpstats). Allele
and genotype frequencies were calculated using SNPStats and confirmed by allele counting.
VassarStats (http://faculty.vassar.edu/lowry/VassarStats.html) was used to calculate odds
ratios (OR) with 95% confidence intervals (CI). Association between c.2771G>A genotype
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and phenotype was assessed using Mann-Whitney tests (GraphPad Prism v 5.00, San Diego,
CA, USA). p values <0.05 were considered significant in all tests.
In silico analysis
Predicted effect of c.2771G>A and c.5843-8C>G on mRNA splicing was examined using;
Splice Site Prediction by Neural Network (http://fruitfly.org:9005/seq_tools/splice.html),
WebGene Splice View (http://zeus2.itb.cnr.it/~webgene/wwwspliceview.html), NetGene2
(http://www.cbs.dtu.dk/services/NetGene2/), Human Splicing Finder (http://www.umd.be/
SSF/).
Results
c.2771G>A phenotype in MCMDM-1VWD family members
The variant c.2771G>A (p.R924Q) was previously identified in IC from four of 150
MCMDM-1VWD families [1]. Regenotyping all IC for the variant led to its additional
identification in IC P8F1II:1 and P9F14II:2. The latter individual was excluded from the
previous cohort [1] due to very low plasma VWF level and virtually undetectable multimers.
The six IC and their AFM have the variant c.2771G>A in heterozygous and homozygous
(P6F11II:4) forms and in compound heterozygous and allelic combinations with further
mutations. They originate from five European countries; their mutation and phenotype data
are shown in Table 1.
P8F1II:1 was heterozygous for c.2771G>A alone, but had an unusually high bleeding score
(BS) of 15 (normal <4) [9] and a further defect in VWF or elsewhere may contribute to her
phenotype. Levels of VWF and FVIII:C were lower in compound heterozygous IC P6F5II:1
and P6F11II:1 and BS was considerably higher than in their heterozygous relatives who
possessed only the non-c.2771G>A familial mutation. Observations on this limited number
of cases suggest that the allele may contribute to reduced VWF and FVIII levels.
Phenotypes in five simple c.2771G>A heterozygotes with normal VWF multimers (1 IC, 2
AFM and 2 UFM) were variable. Median BS was 3, FVIII:C 77 IU/dL, VWF:RCo 69 IU/dL
and VWF:Ag 64 IU/dL. Factor VIII binding (VWF:FVIIIB) data was available for three of
these c.2771G>A heterozygotes and for 63 UFM with no mutations identified. Mean values
for ability of VWF to bind FVIII of 1.07 vs 1.06 was obtained for each group (normal range
0.68-1.44), indicating that a VWF:FVIIIB defect was unlikely in c.2771G>A heterozygotes.
c.2771G>A frequency in healthy controls
The c.2771A allele was present in 35 of 1115 HC. No A allele homozygotes were identified.
Frequency of the c.2771A allele did not differ significantly between IC and HC (2.0% vs
1.6%, odds ratio (OR) 1.30 (95% CI 0.54-3.15). It was identified in 1-4 HC from the
approximately 100 HC recruited by each EU partner, with the exception of P9 (Czech
Republic), where it was present in ten of 98 HC (10.2%). There was no significant
difference in frequency between IC and HC with the removal of P9 data. Genotype
distributions did not significantly deviate from Hardy-Weinberg equilibrium in IC or HC.
However, a comparison of data from Canadian and UK type 1 VWD studies (Table 2)
indicated a slight elevation in frequency of c.2771G>A in IC compared with HC when all
studies were combined (OR 1.99 (95% CI 1.14-3.45)).
The c.2771A allele is associated with a common haplotype
Haplotype analysis using eight SNP was performed in families with c.2771G>A to
determine whether a shared common founder was likely. Five haplotypes were identical
(Table 3), whilst two differed only in the promoter (P6F11a) or 3′ of exon 35 (P9F14).
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Haplotypes were predicted for the c.2771G>A heterozygous HC using SNPStats. The most
frequent (22%) predicted haplotype bearing c.2771A was identical to the common haplotype
in patients. Visual inspection of genotypes indicated that 30 of 35 were consistent with the
common core c.2771A haplotype, whereas in five cases, homozygosity for the alternative
allele at ≥1 position made possession of the common haplotype less likely (Supplementary
table 4). In two HC, haplotype differed only at promoter variant c.-2527A>G, as seen in
P6F11a. c.2771A was in strong linkage disequilibrium (D’=0.997) with the rare G allele of
variant c.5843-8C>G located within the exon 35 acceptor splice site. Presence of c.5843-8G,
found in only ~3% of the Caucasian population, makes it unlikely that c.2771A and c.
5843-8G occur together by chance in the majority of individuals. Absence of c.5843-8G,
plus homozygosity for the alternative nucleotide at additional positions made possession of
the predicted founder haplotype much less likely in three (9%) remaining HC.
c.2771 genotype association with VWF and FVIII levels
Association of the c.2771A allele with VWF:Ag and VWF:RCo levels was investigated in
HC (Fig. 1A; Table 4). VWF:Ag levels only differed significantly in individuals with ABO
blood group O, where c.2771G>A heterozygotes had lower median VWF:Ag levels (~14%)
than c.2771G homozygotes. c.2771 genotype had no influence on VWF:RCo/VWF:Ag
ratios.
Median FVIII:C levels were significantly lower (~20%) in c.2771G>A heterozygotes in
comparison with c.2771G homozygotes in both ABO blood group O and non-O HC (Fig.
1B; Table 4). FVIII:C/VWF:Ag ratios were lower in c.2771G>A heterozygotes than in c.
2771G homozygotes before ABO blood group stratification and in non-O HC c.2771G>A
heterozygotes compared to c.2771G homozygotes (Table 4).
In vitro expression analysis of p.R924Q
Recombinant VWF (rVWF) comprising wt (c.2771G), mutant (c.2771A) or a 50:50 mix
mimicking heterozygosity was transiently transfected into 293 EBNA cells. Secreted and
intracellular VWF levels measured three days post-transfection were very similar for all
transfections. rVWFR924Q and rVWFwt multimers were identical (Fig. 2). In this model
system, p.R924Q as sole genetic variant did not result in altered VWF expression.
In silico assessment of c.2771G>A and c.5843-8C>G variants
None of four in silico splice site analysis tools predicted a significant effect of c.2771G>A
on strength of adjacent splice sites. c.5843-8C>G was predicted by each of four splice site
prediction tools to lead to a minor reduction in splicing efficiency (~3%), predicting the rare
G allele would function less well than the C allele.
The allele bearing p.R924Q appears not to behave as a null allele
Median VWF:Ag levels in 35 HC c.2771G>A heterozygotes and five family members who
were heterozygous only for c.2771G>A were 87 IU/dL and 64 IU/dL respectively (Tables 1
and 4). The lowest VWF:Ag level observed among these 41 individuals was 49 IU/dL in 1
HC and 1 IC. Nichols et al [12] compiled data on 190 heterozygous relatives of type 3 VWD
patients, the majority of whom would have a null allele [13]. Mean VWF:Ag was 47 IU/dL
(range ±2SD 16-140 IU/dL), considerably lower than in p.R924Q heterozygotes.
Additionally, the single c.2771A homozygous AFM (P6F11II:4) had VWF and FVIII levels
only slightly lower than in heterozygous individuals (VWF:RCo 50 IU/dL; VWF:Ag 49 IU/
dL). c.2771G>A behaviour is thus unlike that of a null allele.
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Discussion
Previous studies have identified p.R924Q in healthy controls, patients with VWD and their
unaffected relatives [2-6,14], but have not reached a conclusion regarding its pathogenic
significance. The current study has demonstrated that the p.R924Q allele does have an effect
on phenotype in heterozygous HC. The extent of its influence on VWF and FVIII levels is
modest and analysis in a larger group of individuals may be required to appreciate the
degree of effect on VWF levels. Blood group O c.2771G>A heterozygous HC had VWF:Ag
and FVIII:C levels approximately 35% lower than c.2771G homozygotes with non-O blood
groups. Approximately 10% variance was attributable to the A allele and the remainder to
blood group O. The p.R924Q allele and blood group O displayed an additive effect, similar
to that associated with the p.Y1584C variant, where an additive effect (~25%) of the allele
with blood group O was observed [15]. Slightly enhanced VWF clearance could contribute
to lower levels observed in individuals bearing p.R924Q, as seen for p.Y1584C [15].
Limited data on clearance derived from follow-up of desmopressin administration and ratios
of VWF propeptide to VWF:Ag (VWFpp/VWF:Ag) are available. IC P7F3II:1 (p.[R924Q]+
[R854Q]) was included in a desmopressin response study [16] and was not amongst cases
demonstrating increased clearance (VWF:RCo half-life <4 hr). VWFpp/VWF:Ag ratios
have recently been determined. Mean ratio of 1.30 in four simple p.R924Q heterozygous
family members was not different from the mean ratio of 1.32 in 376 c.2771G homozygous
HC. Therefore, enhanced clearance is unlikely to explain reduced VWF levels.
In EU IC, heterozygous inheritance of p.R924Q alone appeared insufficient for VWD
symptoms, although in other type 1 VWD studies, only a small proportion of IC (3 of 10 [5]
and 2 of 8 [2]) had further mutations identified. In five of six EU IC heterozygous for
p.R924Q, a second VWF sequence variant seems to contribute to phenotype. In P8F1II:1, a
further factor may contribute to bleeding. Phenotypic modifiers, for example platelet defects
have been shown to influence bleeding propensity in type 1 VWD [17]. Many factors can
influence VWF levels including age, stress and hormonal status. The extent of effect on
VWF levels attributable to the c.2771G>A allele may be confounded by ABO and other
blood groups including Lewis [18] and Secretor [19]. Further loci influencing VWF levels
have been sought but await characterisation [20].
In vitro expression of recombinant p.R924Q VWF showed no reduced secretion, increased
intracellular retention or alteration in VWF multimers and in silico analysis predicted no
effect of c.2771G>A on intron 20 acceptor/intron 21 donor splice sites. A recent study using
a different model system also indicated lack of evidence for effect of p.R924Q on VWF
expression level [6].
The majority of p.R924Q alleles are likely to be identical by descent. Occurrence of c.
5843-8G consistently on the same allele as c.2771A was also reported by Lester et al [5].
Elevated p.R924Q frequency in Czech HC (10.2% vs 2.5% in all other HC) may indicate an
Eastern European origin. p.R924Q was absent from 183 unrelated Argentinian blood donors
[14], further supporting a European origin. Three (9%) of 35 heterozygous HC were unlikely
to share the common haplotype through identity by descent. c.2771G>A occurs at a CpG
dinucleotide, a relative mutation hotspot and it is possible that in addition to its occurrence
on the founder haplotype, the G>A substitution has arisen independently. Berber et al
comment that c.5843-8G was not consistently identified on c.2771A alleles [6], suggesting
that some de novo c.2771G>A cases were present among Canadian subjects. Independent
occurrence of c.2771G>A, along with additional sequence variants arising on the founder
haplotype as seen in both the current and UK studies [3,5], likely helps to explain variable
behaviour of p.R924Q alleles. As suggested by Berber et al [6], “not all p.R924Q alleles are
created equal.”
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Cumming et al [3] analysed platelet VWF mRNA from a patient heterozygous for c.[2771A
+5843-8G] and identified a single normal VWF transcript in the region surrounding intron
34, with no evidence of aberrant splicing. As it is improbable given its position relative to
exon 34 that c.5843-8C>G results in complete lack of VWF expression, any significant
effect on VWF mRNA appears unlikely. Cumming’s result neither supports nor refutes
Berber’s identification of abnormal mRNA resulting from exon 28 cryptic splice site
activation, as if the p.R924Q allele bears a mutation resulting in a truncated mRNA, aberrant
mRNA may not extend as far as exon 34.
In conclusion, the p.R924Q variant marks a VWF allele found in approximately 3% of
Caucasians, of which the majority are likely to be identical by descent. The allele is
associated with reductions in VWF and FVIII:C levels particularly when co-inherited with
blood group O. The missense alteration p.R924Q alone in an in vitro model does not lead to
altered protein expression and neither recombinant VWF nor the allele in heterozygous
individuals reduces VWF:FVIIIB in a static system nor affect clearance. The effect of the
allele may therefore be that of a further, as yet unidentified sequence variant in strong
linkage disequilibrium with p.R924Q.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. Association between genotypes at c.2771, VWF:Ag and FVIII:C levels in healthy controls
according to ABO blood group
*, ** and ***indicate significant (p<0.05, p<0.01 and p<0.0001, Mann-Whitney test)
differences between median values of (A) VWF:Ag and (B) FVIII:C amongst HC,
depending on their c.2771 genotype. “All” refers to the entire HC population, “O” = blood
group O and “Non-O” = blood groups other than O.
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Fig. 2. Expression of recombinant VWF in 293 EBNA cells
(A) rVWF secreted into the medium and retained within the cell relative to rVWFwt alone.
(B) Profile of secreted rVWFR924Q multimers electrophoresed on SDS-agarose (1.2%).
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Table 3
VWF haplotype analysis of individuals carrying p.R924Q in type 1 VWD families
Sequence
variant
Reported
allele
frequency*
Family ID
P3F13 P6F5 P6F11a‡ P6F11b‡ P7F3 P9F14 P8F1 Commonhaplotype
Promoter
c.-2527A>G 0.68/0.32
† A A G A A A A A
Exon 12
c.1411G>A
p.V411I
0.45/0.55† G G G G G G G G
Exon 18
c.2365A>G
p.T789A
0.66/0.34 A A A A NI A A A
Exon 21
c.2771G>A
p.R924Q
0.98/0.02 A A A A A A A A
Exon 28
c.4141G>A
p.T1381A
0.62/0.38 G G G G G G NI G
Intron 34
c.5843-8C>G 0.97/0.03
† G G G G G G NI G
Exon 35
c.5844C>T
p.C1948
0.63/0.37 C C C C C C NI C
Intron 49
c.8116-20A>C 0.78/0.22 A A A A A C A A
Intron 50
c.8155+50C>T 0.87/0.13 C C C C C T C C
*Caucasian frequency, reported on http://www.ncbi.nlm.nih.gov/SNP (Hap-Map European) or
†http://www.vwf.group.shef.ac.uk/
‡
Haplotypes a and b were present in the same family; both parents were c.2771G>A heterozygous, the AFM was homozygous.
NI = non-informative.
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